Literature DB >> 21567969

Dopamine D₂/D₃ agonists with potent iron chelation, antioxidant and neuroprotective properties: potential implication in symptomatic and neuroprotective treatment of Parkinson's disease.

Sanjib Gogoi1, Tamara Antonio, Subramanian Rajagopalan, Maarten Reith, Julie Andersen, Aloke K Dutta.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21567969      PMCID： PMC3492952          DOI： 10.1002/cmdc.201100140

Source DB:  PubMed          Journal:  ChemMedChem        ISSN： 1860-7179            Impact factor:   3.466


× No keyword cloud information.
  33 in total

1.  The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity.

Authors:  N Ostrerova-Golts; L Petrucelli; J Hardy; J M Lee; M Farer; B Wolozin
Journal:  J Neurosci       Date:  2000-08-15       Impact factor: 6.167

2.  Novel D3 dopamine receptor-preferring agonist D-264: Evidence of neuroprotective property in Parkinson's disease animal models induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and lactacystin.

Authors:  Chao Li; S Biswas; Xingang Li; A K Dutta; Weidong Le
Journal:  J Neurosci Res       Date:  2010-08-15       Impact factor: 4.164

Review 3.  Iron and Parkinson's disease.

Authors:  Benjamin Wolozin; Natalie Golts
Journal:  Neuroscientist       Date:  2002-02       Impact factor: 7.519

4.  Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease.

Authors:  Deepinder Kaur; Ferda Yantiri; Subramanian Rajagopalan; Jyothi Kumar; Jun Qin Mo; Rapee Boonplueang; Veena Viswanath; Russell Jacobs; Lichuan Yang; M Flint Beal; Dino DiMonte; Irene Volitaskis; Lisa Ellerby; Robert A Cherny; Ashley I Bush; Julie K Andersen
Journal:  Neuron       Date:  2003-03-27       Impact factor: 17.173

5.  6-Hydroxy-dopamine induced degeneration of central monoamine neurons.

Authors:  U Ungerstedt
Journal:  Eur J Pharmacol       Date:  1968-12       Impact factor: 4.432

6.  Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease.

Authors:  Baptiste A Faucheux; Marie-Elise Martin; Carole Beaumont; Stéphane Hunot; Jean-Jacques Hauw; Yves Agid; Etienne C Hirsch
Journal:  J Neurochem       Date:  2002-10       Impact factor: 5.372

7.  Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease.

Authors:  Jin Xu; Shyan-Yuan Kao; Frank J S Lee; Weihong Song; Lee-Way Jin; Bruce A Yankner
Journal:  Nat Med       Date:  2002-06       Impact factor: 53.440

Review 8.  Brain iron pathways and their relevance to Parkinson's disease.

Authors:  D Berg; M Gerlach; M B Youdim; K L Double; L Zecca; P Riederer; G Becker
Journal:  J Neurochem       Date:  2001-10       Impact factor: 5.372

9.  "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy.

Authors:  C D Marsden; J D Parkes
Journal:  Lancet       Date:  1976-02-07       Impact factor: 79.321

Review 10.  Ironing out Parkinson's disease: is therapeutic treatment with iron chelators a real possibility?

Authors:  Deepinder Kaur; Julie K Andersen
Journal:  Aging Cell       Date:  2002-10       Impact factor: 9.304
View more
  12 in total

1.  Structure-activity relationship study of N⁶-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N⁶-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine analogues: development of highly selective D3 dopamine receptor agonists along with a highly potent D2/D3 agonist and their pharmacological characterization.

Authors:  Mark Johnson; Tamara Antonio; Maarten E A Reith; Aloke K Dutta
Journal:  J Med Chem       Date:  2012-06-13       Impact factor: 7.446

2.  Efficacy of Hybrid Tetrahydrobenzo[d]thiazole Based Aryl Piperazines D-264 and D-301 at D₂ and D₃ Receptors.

Authors:  Maarten E A Reith; Aloke K Dutta; Dana E Selley; Juan Zhen; Tamara Antonio; Joanna C Jacob; David K Grandy
Journal:  Neurochem Res       Date:  2015-12-31       Impact factor: 3.996

Review 3.  Advances and challenges in the search for D2 and D3 dopamine receptor-selective compounds.

Authors:  Amy E Moritz; R Benjamin Free; David R Sibley
Journal:  Cell Signal       Date:  2017-07-14       Impact factor: 4.315

4.  The high-affinity D2/D3 agonist D512 protects PC12 cells from 6-OHDA-induced apoptotic cell death and rescues dopaminergic neurons in the MPTP mouse model of Parkinson's disease.

Authors:  Mrudang Shah; Subramanian Rajagopalan; Liping Xu; Chandrashekhar Voshavar; Yevgeniya Shurubor; Flint Beal; Julie K Andersen; Aloke K Dutta
Journal:  J Neurochem       Date:  2014-06-21       Impact factor: 5.372

5.  D-512 and D-440 as novel multifunctional dopamine agonists: characterization of neuroprotection properties and evaluation of in vivo efficacy in a Parkinson's disease animal model.

Authors:  Soumava Santra; Liping Xu; Mrudang Shah; Mark Johnson; Aloke Dutta
Journal:  ACS Chem Neurosci       Date:  2013-08-20       Impact factor: 4.418

6.  Multifunctional D2/D3 agonist D-520 with high in vivo efficacy: modulator of toxicity of alpha-synuclein aggregates.

Authors:  Gyan Modi; Chandrashekhar Voshavar; Sanjib Gogoi; Mrudang Shah; Tamara Antonio; Maarten E A Reith; Aloke K Dutta
Journal:  ACS Chem Neurosci       Date:  2014-07-09       Impact factor: 4.418

7.  Understanding the Structural Requirements of Hybrid (S)-6-((2-(4-Phenylpiperazin-1-yl)ethyl)(propyl)amino)-5,6,7,8-tetrahydronaphthalen-1-ol and its Analogs as D2/D3 Receptor Ligands: A Three-Dimensional Quantitative Structure-Activity Relationship (3D QSAR) Investigation.

Authors:  Gyan Modi; Horrick Sharma; Prashant S Kharkar; Aloke K Dutta
Journal:  Medchemcomm       Date:  2014-09-01       Impact factor: 3.597

8.  Development of a Highly Potent D2/D3 Agonist and a Partial Agonist from Structure-Activity Relationship Study of N(6)-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Implication in the Treatment of Parkinson's Disease.

Authors:  Banibrata Das; Seenuvasan Vedachalam; Dan Luo; Tamara Antonio; Maarten E A Reith; Aloke K Dutta
Journal:  J Med Chem       Date:  2015-11-30       Impact factor: 7.446

9.  Design, synthesis, and structure-activity relationship studies of a series of [4-(4-carboxamidobutyl)]-1-arylpiperazines: insights into structural features contributing to dopamine D3 versus D2 receptor subtype selectivity.

Authors:  Subramaniam Ananthan; Surendra K Saini; Guangyan Zhou; Judith V Hobrath; Indira Padmalayam; Ling Zhai; J Robert Bostwick; Tamara Antonio; Maarten E A Reith; Shea McDowell; Eunie Cho; Leah McAleer; Michelle Taylor; Robert R Luedtke
Journal:  J Med Chem       Date:  2014-08-15       Impact factor: 7.446

10.  A delicate balance: Iron metabolism and diseases of the brain.

Authors:  Dominic Hare; Scott Ayton; Ashley Bush; Peng Lei
Journal:  Front Aging Neurosci       Date:  2013-07-18       Impact factor: 5.750
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.